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Abstract
Background: Caesarean section is one of the most commonly performed major operations in
women throughout the world. Rates are escalating, with studies from the United States of America,
the United Kingdom, China and the Republic of Ireland reporting rates between 20% and 25%.
Operative morbidity includes haemorrhage, anaemia, blood transfusion and in severe cases,
maternal death.
The value of routine oxytocics in the third stage of vaginal birth has been well established and it has
been assumed that these benefits apply to caesarean delivery as well. A slow bolus dose of oxytocin
is recommended following delivery of the baby at caesarean section. Some clinicians use an
additional infusion of oxytocin for a further period following the procedure. Intravenous oxytocin
has a very short half-life (4–10 minutes) therefore the potential advantage of an oxytocin infusion
is that it maintains uterine contractility throughout the surgical procedure and immediate
postpartum period, when most primary haemorrhages occur. The few trials to date addressing the
optimal approach to preventing haemorrhage at caesarean section have been under-powered to
evaluate clinically important outcomes. There has been no trial to date comparing the use of an
intravenous slow bolus of oxytocin versus an oxytocin bolus and infusion.
Methods and design: A multi-centre randomised controlled trial is proposed. The study will take
place in five large maternity units in Ireland with collaboration between academics and clinicians in
the disciplines of obstetrics and anaesthetics. It will involve 2000 women undergoing elective
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caesarean section after 36 weeks gestation. The main outcome measure will be major haemorrhage
(blood loss >1000 ml). A study involving 2000 women will have 80% power to detect a 36% relative
change in the risk of major haemorrhage with two-sided 5% alpha.
Discussion:  It is both important and timely that we evaluate the optimal approach to the
management of the third stage at elective caesarean section. Safe operative delivery is now a
priority and a reality for many pregnant women. Obstetricians, obstetric anaesthetists, midwives
and pregnant women need high quality evidence on which to base management approaches. The
overall aim is to reduce maternal haemorrhagic morbidity and its attendant risks at elective
caesarean section.
Trial registration: number: ISRCTN17813715
Background
Systematic review of literature
Caesarean section is one of the most commonly per-
formed major operations in women throughout the
world. Rates are escalating, with studies from the devel-
oped world reporting rates between 20% and 25%. [1-3]
Rates vary considerably between centres within Ireland.
[4]There are many possible approaches to performing a
caesarean section, the aim being to achieve safe delivery of
the infant with a minimum of maternal morbidity. Oper-
ative morbidity includes haemorrhage, anaemia, blood
transfusion and the risks associated with receiving donor
blood products. In severe cases it may result in hysterec-
tomy, admission to an intensive care unit or death.
The active management of the third stage at caesarean sec-
tion has received little attention to date. The value of rou-
tine oxytocics in the third stage of vaginal birth has been
well established [5] and it has been assumed that these
benefits apply to caesarean delivery as well. [6,7] The
Royal College of Obstetricians and Gynaecologists
(RCOG) Guideline on caesarean section recommends a
slow intravenous bolus dose of 5 IU of oxytocin following
delivery of the infant. [8] This is a lower dose than used
previously by many obstetric anaesthetists (10–20 IU) [9]
and is based on concerns about side effects such as mater-
nal hypotension. [10] Conversely, a conservative
approach to the use of oxytocin may increase the risk of
haemorrhage.
Intravenous oxytocin has a very short half-life (4–10 min-
utes) therefore the potential advantage of an oxytocin
infusion at caesarean section is that it maintains uterine
contractility throughout the surgical procedure and
immediate postpartum period, when most primary haem-
orrhages occur. Several randomised controlled trials have
compared intravenous oxytocin with oral misoprostol,
15-methyl prostaglandin F2 alpha and carbetocin, report-
ing little evidence of benefit with the newer agents. [6,11-
13] There has been no trial to date comparing the simpler
approach of an intravenous slow bolus of oxytocin versus
an oxytocin bolus and infusion. Both approaches are
employed within current obstetric practice but there is
great variation in the approach of individual clinicians
and institution. There is very limited evidence to guide
practice.
A search of Medline and Embase from 1965 to 2006 and
of the Cochrane Library was undertaken, for relevant sys-
tematic reviews, meta-analyses, randomised controlled
trials, and other clinical trials. The date of the last search
was September 2006. We intend to update this as part of
a Cochrane Systematic Review, but at the time of planning
and starting the trial, there were no key changes since the
search of September 2006. The main keywords used were:
caesarean section, blood loss, haemorrhage, oxytocin,
uterotonic agent, embolic agent, randomised controlled
trial. In addition, when reviewing published reference
lists, key articles cited were also retrieved and reviewed.
The review of the literature has been divided into use of
oxytocin at varying doses and comparative use of alterna-
tive uterotonic agents.
The literature relating to the use of oxytocin bolus doses at
caesarean section is presented in Table 1. The current rec-
ommendation is to use a slow bolus of 5 IU intravenously
after clamping of the cord. [8] Various approaches have
been tested and it is possible that smaller doses (0.3 – 5
IU) may be sufficient for elective caesarean section. [14]
Nonetheless we plan to use a 5 IU bolus of oxytocin
within the trial in keeping with current recommended
practice. Various alternative uterotonic agents have been
evaluated in randomised controlled trials. (Table 2) Most
published trials to date have had between 30 and 50 par-
ticipants and have been under-powered to detect impor-
tant clinical outcomes such as major haemorrhage and
anaemia. The largest trial of over 500 women used "need
for an additional uterotonic agent" as the primary out-
come measure.
We propose to compare the simpler approach of oxytocin
bolus versus oxytocin bolus and infusion. This willBMC Pregnancy and Childbirth 2009, 9:36 http://www.biomedcentral.com/1471-2393/9/36
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address the question whether an inexpensive and widely
used drug can be employed in a more optimal way to pre-
vent haemorrhage at caesarean section. We will be able to
establish the number needed to treat to prevent one case
of major haemorrhage with reasonable confidence limits.
The hypothesis is that an oxytocin infusion used in addi-
tion to an oxytocin bolus at elective caesarean section will
reduce the risk of major haemorrhage and anaemia.
National survey of current practice
Prior to undertaking this study it is important to establish
current practice and the support for such a trial. A ques-
tionnaire was developed, composed of a series of closed
answer questions with additional space for free text com-
ments. The questionnaire focussed on the clinicians' use
of oxytocin at caesarean section, perceived frequency of
side effects, estimated average blood loss, rates of haemor-
rhage and willingness to participate in a future clinical
Table 1: Published studies evaluating doses of oxytocin (syntocinon)
Author, citation Study design Exposures Outcome measures Results Conclusions
Sarna MC et al
Anesth Analg 1997
84:753–6.
RCT
40 women
Elective CS/regional
Oxytocin after cord 
clamping
5 IU vs 10 IU vs 15 IU 
vs 20 IU
Linear analogue of 
uterine tone
EBL
ΔHCT 
(pre-op/post-op)
No difference in any 
outcomes
No benefit in doses 
exceeding 5 IU
Zarzur
Anesth Analg 1998
86:1334.
Dose-finding
20 women
Elective CS
Oxytocin dosing Uterine contractility
Side effects
3 IU oxytocin
Satisfactory
No side effects
Low dose 3 IU 
sufficient
Carvalho JC et al
Obstet Gynecol 2004
104:1005–10.
Dose-finding
RCT single blind
40 women
Elective CS/regional
Titrating increments of 
0.5 IU oxytocin bolus
Infusion 2.4 IU/hr
Minimum effective 
dose ED
Uterine contraction
EBL (calculated)
ED90 at 0.35 IU
100% at 1.0 IU
Low dose bolus < 5 IU 
effective
Balki M et al
Obstet Gynecol 2006
107:45–50.
Dose-finding
RCT single blind
30 women
CS for labor arrest
Titrating increments of 
0.5 IU oxytocin bolus
Infusion 2.4 IU/hr
Minimum effective 
dose ED
Uterine contraction
EBL (calculated)
ED90 at 3.0 IU Much higher dose than 
for elective CS
Suggest alternative 
agent for non-elective
Table 2: Published studies comparing oxytocin (syntocinon) with alternative uterotonic agents
Author, citation Study design Exposures Outcome measures Results Conclusions
Catanzarite VA et al
Am J Perinatol
1990;7:39–42.
RCT double blind
46 women
Elective CS
Oxytocin 20 IU iv bs 
PGF2α125 mcg im
After placenta 
delivered
ΔHCT (EBL) No difference in EBL No benefit with 
carboprost
Chou MM et al
Am J Obstet Gynecol
1994;171:1356–60.
RCT double blind
60 women
Elective CS
Oxytocin 20 IU iv vs 
PGF2α125 mcg im
EBL
ΔHCT, ΔHb
Side effects (SE)
No significant 
differences
No benefit with 
carboprost
Boucher M et al
J Perinatol
1998;18:202–7.
RCT double blind
57 women
Elective CS
Oxytocin infusion
16 hr vs
Carbetocin 100 mcg iv
EBL
Side effects
Carbetocin as effective
Lower EBL
Carbetocin as effective/
reliable
Dansereau J et al
Am J Obstet Gynecol
1999;180:670–6.
RCT double blind
635 women
Elective CS
Oxytocin infusion
8 hr vs
Carbetocin 100 mcg iv
Need for additional 
uterotonic agent
Carbetocin more 
effective
10% vs 4.7%
Carbetocin more 
effective than infusion 
only
Acharya G et al
Acta Obst Gyn Scand
2001;80:245–50.
RCT single blind
60 women
Elective CS/regional
Oxytocin 10 IU iv vs
Misoprostol 400 mcg 
po
EBL, HCT, Hb,
Side effects
No difference
No SE
Misoprostol as safe/
effective as 10 IU 
oxytocin
Lokugamage AU et al
Aus NZ J Obst Gyne
2001;41:411–4.
RCT double blind
40 women
Elective/Em CS
Oxytocin 10 IU iv vs
Misoprostol 400 mcg 
po
EBL
ΔHb
Additional uterotonic
No difference Misoprostol an 
alternative to 10 IU
Need for large RCTBMC Pregnancy and Childbirth 2009, 9:36 http://www.biomedcentral.com/1471-2393/9/36
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trial. The questionnaire was sent to the lead consultant
obstetrician and lead obstetric anaesthetist in all consult-
ant-led obstetric units in the United Kingdom. Analysis
was performed using SPSS Version 13.0 for windows. The
findings of this survey are reported in detail in the Euro-
pean Journal of Obstetrics & Gynaecology and Reproduc-
tive Biology. [15]
Of the 434 questionnaires sent, 365 clinicians replied
(response rate 84%), with none indicating that the ques-
tionnaire was inapplicable to their practice. Among the
responders, 49% were lead obstetric consultants and 51%
were lead obstetric anaesthetists. The various approaches
to the use of oxytocin at the time of caesarean section are
presented in Table 3. A slow bolus of 5 IU oxytocin was
the preferred approach of obstetricians and anaesthetists
(153, 86% and 171, 92% respectively). Routine oxytocin
infusions were used by 72 clinicians (20%), and selective
infusions were used for particular clinical situations by
289 (80%). Most clinicians used either 30 IU (158, 43%)
or 40 IU (192, 53%) infusions over 4 hours, with a total
of 38 different regimens. The perceived risk of side effects
with oxytocin was low, particularly for infusions. Esti-
mated "average" blood loss varied (150–1500 ml) with
56 clinicians (17%) and 93 (28%) reporting a >20% risk
of postpartum haemorrhage for elective and emergency
caesarean sections, respectively.
This national survey of practice in the use of oxytocin for
the prevention of blood loss at caesarean section found
general consistency in the use of bolus oxytocin but a
great deal of variation in the use of additional oxytocin
infusions. The perceived risk of side effects with oxytocin
was low, particularly for infusions. Obstetricians and
anaesthetists reported a high rate of excess haemorrhage
at caesarean section and more than half of the clinicians
surveyed would participate in a randomised controlled
trial comparing oxytocin bolus with bolus and infusion.
There is wide variation in the approach to prevention of
haemorrhage at caesarean section, reflecting a lack of
robust evidence. This survey supports the need for further
research into this important aspect of intrapartum care.
The preferred approach was to use a 40 IU infusion of oxy-
tocin in a solution of 0.9% saline in keeping with the rec-
ommendations of the Advanced Life Support in
Obstetrics (ALSO) courses. This is the regimen we plan to
use for the proposed trial.
The survey was carried out within the UK as the original
plan (prior to relocation of the PI) was to conduct the
study in Scotland. The practice of clinicians in Ireland is
very similar to reported practice in the UK.
The hypothesis is that an oxytocin infusion used in addi-
tion to an oxytocin bolus at elective caesarean section will
reduce the risk of major haemorrhage and anaemia.
Aims and objectives
The aim of this study is to compare the effects of an intra-
venous slow bolus of oxytocin (5 IU) and placebo infu-
sion (500 ml 0.9% saline) with an intravenous slow bolus
of oxytocin (5 IU) and oxytocin infusion (40 IU in 500 ml
0.9% saline over 4 hours) at elective caesarean section in
a double blind randomised trial.
Specific objectives are as follows:
Primary outcomes
- to compare the incidence of major obstetric haemor-
rhage (≥ 1000 ml) following oxytocin bolus compared
with oxytocin bolus and infusion
- to compare the need for an additional uterotonic
agent between the two groups
Major obstetric haemorrhage will be defined by:
- measured blood loss as calculated from pre and post-
operative haematocrit (see below)
Secondary outcomes
- to compare the estimated mean operative blood loss
between the two groups (as measured by theatre staff)
- to compare early lochial loss following oxytocin
bolus compared with oxytocin bolus and infusion
Table 3: Percentages refer to complete responses
All
n = 365 (%)
Obstetricians
n = 179 (%)
Anaesthetists
n = 186 (%)
Slow bolus 5 IU oxytocin 324 (89.5) 153 (86.4) 171 (92.4)
Slow bolus 10 IU oxytocin 44 (12.1) 28 (15.6) 16 (8.6)
Additional 5 IU bolus if clinically indicated 61 (17.0) 17 (9.5) 44 (23.5)
Routine use of oxytocin infusion 72 (19.8) 33 (18.4) 39 (21.1)
Selective use of oxytocin infusion 289 (79.8) 145 (81.0) 144 (78.7)
30 IU oxytocin infusion 158 (43.3) 83 (46.4) 76 (40.9)
40 IU oxytocin infusion 192 (53.3) 90 (50.8) 102 (55.0)
Approaches to the use of oxytocin at the time of caesarean sectionBMC Pregnancy and Childbirth 2009, 9:36 http://www.biomedcentral.com/1471-2393/9/36
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- to compare the objective change in haemoglobin and
haematocrit before and 48 hours after delivery
between the two groups
- to compare the incidence of severe anaemia (Hb fall
≥ 20%) 48 hours after delivery between the two groups
(or patient transfused).
- to compare the need for blood transfusion and/or
blood products
- to compare the incidence of side effects (vomiting,
hypotension)
- to compare the postnatal length of stay in theatre/
recovery and in the hospital
Cost-effectiveness
- to compare the cost-effectiveness of an oxytocin
bolus regimen versus oxytocin bolus and infusion
(separate protocol).
Methods and design
Recruitment and allocation
Inclusion criteria
The study will be limited to healthy women at term (> 36
weeks) with singleton pregnancies who are booked for
elective caesarean section.
Exclusion criteria
Women with placenta praevia, thrombocytopenia, coagu-
lopathies, a previous major obstetric haemorrhage (≥
1000 ml), known fibroids or receiving anti-coagulant
therapy will be excluded as will women who do not
understand English and women under the age of 18 years.
Other patients may be excluded at the clinician's discre-
tion if a major haemorrhage is anticipated.
Women will be recruited to the trial in the third trimester
when initial arrangements are being made for a booked
elective caesarean section. The antenatal clinic midwife or
research midwife/fellow will approach eligible women
and offer information about the study. Women return on
the day of surgery and spend a number of hours on the
day ward or antenatal ward prior to surgery. At that point
the woman's interest in participation in the study will be
confirmed, an opportunity to ask additional questions
will be provided and informed written consent will be
completed. Randomisation will be performed using an
automated web-based randomisation system hosted by
the Bristol Randomised Trials Collaboration, a UKCRN-
registered trials unit. Allocation will be stratified by centre
and previous caesarean section (no/yes), and blocked
using random permuted blocks of varying size.
The active or placebo infusion will be prepared by the
research fellow/midwife. This will be done in the phar-
macy department, away from theatre and will be labelled
as "Trial drug – Placebo or 40 IU oxytocin". This will
ensure blinding of everyone except the research fellow
who makes up the infusion, and they will have no role in
the management of the patient. Having the research fel-
low blinded is not possible for two reasons. Firstly, it is
not possible to pre-prepare the infusions due to a lack of
knowledge of the stability of oxytocin. Secondly, it has not
been possible to obtain identically matched placebo
ampoules.
Intervention
Following written informed consent women will be ran-
domised to receive either an intravenous slow bolus of
oxytocin 5 IU and a placebo infusion (0.9% saline solu-
tion 500 ml over 4 hours), or oxytocin bolus 5 IU and oxy-
tocin infusion (40 units in 500 ml 0.9% saline over 4
hours). Both the patient and the health care staff will be
blinded to the intervention. The hospital pharmacist will
produce numbered treatment kits containing either 1 × 5
IU ampoule or 1 × 5 IU ampoule and 4 × 10 IU ampoules.
There will be labels and instructions for the research fel-
low to prepare the infusion so that the anaesthetist and
other members of the investigator team remain blinded to
the randomised treatment.
It is important that the surgical approach to caesarean sec-
tion is standardised. Surgeons will be asked to operate to
a standard procedure that specifies controlled cord trac-
tion for delivery of the placenta after administration of the
oxytocin bolus, two layer closure of the uterine incision,
and to avoid delivering the uterus for suturing unless clin-
ically indicated. Deviations from the standard procedure
will be recorded. Should the uterus remain atonic despite
the trial intervention, the obstetrician/anaesthetist can use
an additional uterotonic agent either replacing the trial
infusion with a known infusion of oxytocin and/or use of
a further agent.
Measurement of operative blood loss will be standard-
ised. Disposable waterproof drapes are in use with pockets
that capture all body fluids. The suction volume is meas-
ured. All swabs are weighed to measure additional blood
loss. A more objective measure of blood loss will be calcu-
lated using pre- and post-operative haematocrit (see out-
come measures below).
Anaesthesia will also be standardised. An intravenous
bolus of 500 ml crystalloid should be given to all patients
prior to spinal anaesthesia. A size 25G pencil-point needle
should be used at a suitable lumbar interspace. The
patient can be sitting or in the left lateral position for spi-BMC Pregnancy and Childbirth 2009, 9:36 http://www.biomedcentral.com/1471-2393/9/36
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nal anaesthesia. The anaesthetic solution will consist of 2
ml 0.5% hypertonic bupivocaine (2.2 ml in the sitting
position), 10–20 μg fentanyl and 0.1 mg preservative free
morphine. Anaesthesia should be to the level of T5, as
assessed by touch. The patient will be tilted 15° to the left
of supine and standard monitoring used as per the AAGBI
guidelines. The sphygmomanometer cuff should be
placed on the left arm. Haemodynamic monitoring will
be performed before spinal anaesthesia, every minute
until 10 minutes after delivery, every 15 minutes during
the first postoperative hour then every 30 minutes for 4
hours. For the purpose of this study, baseline haemody-
namic variables will be regarded as those immediately
after clamping of the cord and before administration of
syntocinon 5 IU. The investigators accept that individual
anaesthetists may deviate from this protocol according to
clinical needs. This is acceptable and should be docu-
mented on the case report form.
Intraoperative hypotension will be treated with intrave-
nous boluses of phenylephrine 50 μg. If the heart rate falls
below 60/min, intravenous boluses ephedrine 6 mg will
be substituted. The anaesthetist will aim to maintain
blood pressure at preoperative values. After delivery, the
operating table tilt will be removed and the patient placed
in the full supine position. Blood loss at operation will be
replaced with colloid infusion or blood as deemed neces-
sary by the anaesthetist. Postoperative pain relief will con-
sist of regular non-steroidal analgesia combined with
paracetamol. Opiates in the form of oxynorm can be used
with caution considering the use of intrathecal opiates.
Again it is acceptable for the local administrator to use any
form of analgesia as per local practice and to document it
on the case report form.
Outcome measures
The primary outcome measures are major obstetric haem-
orrhage (estimated blood loss ≥ 1000 ml) and use of an
additional uterotonic agent. Estimated blood loss of
≥1000 ml has been chosen to reflect major obstetric
haemorrhage and it is widely accepted that clinicians
underestimate rather than overestimate blood loss. This
estimate will be based on the difference between pre-oper-
ative and post-operative haematocrit (EBLcalc – Calculated
estimated blood loss). [14]
The estimate is calculated as follows:
Where EBV estimated blood volume = Booking weight in
kg × 85
Secondary outcomes include mean estimated blood loss
(as measured by theatre staff), change in haemoglobin
and haematocrit, significant anaemia (Hb fall = 20%) 48
hours after delivery, need for blood transfusion, side
effects (including vomiting and hypotension) and length
of postnatal stay in theatre/recovery and in hospital.
Hypotension will be defined as a fall in blood pressure of
more than 30% below the pre-operative blood pressure
and/or use of ephedrine.
Follow-up
A routine full blood count will be performed 48 hours
after delivery to assess haemoglobin and haematocrit.
Clinical follow-up of the mother will be completed prior
to hospital discharge.
Trial end
The trial will be considered complete after the final review
of the last trial participant. The end of the trial will be
notified to the Competent Authority and the Ethics Com-
mittee using the appropriate form.
Statistical analysis
Data analysis and reporting will proceed according to
CONSORT guidelines for randomised controlled trials,
and will be conducted blinded to group status by the trial
statistician and researcher. The first stage of analysis will
be to use descriptive statistics to describe recruited indi-
viduals in relation to those eligible, and to investigate
comparability of the trial arms at baseline. The primary
analyses will involve intention-to-treat comparisons
between the two groups for the primary outcomes, with
transformation as appropriate after examination of distri-
butions, and adjusted for stratification variables. Second-
ary analyses will investigate the effects of further
adjustment for any variables displaying marked imbal-
ance between the arms at baseline. Secondary outcomes
will be analysed in a similar way. All analyses will use
appropriate (that is, logistic or linear) regression models,
with results presented as point estimates (odds ratios or
difference in means), 95% confidence intervals and p val-
ues. Further secondary analyses will involve planned sub-
group analyses and will use multivariable regression
models with appropriate interaction terms to ascertain
any differential effects in relation to repeat caesarean sec-
tion, choice of anaesthetic, and operator experience.
Pilot study results
We have completed an initial pilot study that has
informed the study design allowing an estimate of appro-
priate sample size and likely recruitment, alongside an
evaluation of outcome measures. The results of this study
have been published by the European Journal of Obstet-
rics & Gynaecology and Reproductive Biology. [16] The
pilot study represented a single centre randomised con-
trolled trial of oxytocin 5 IU and placebo infusion versus
oxytocin 5 IU bolus and oxytocin 30 IU infusion. We
chose a 30 IU infusion as this was the approach recom-
EBL EBV
Pre-op Hct Post-op Hct
Pre-op Hct
calc =×
− ()BMC Pregnancy and Childbirth 2009, 9:36 http://www.biomedcentral.com/1471-2393/9/36
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mended in the NICE Guideline on induction of labour.
We have changed the study design to a 40 IU infusion
reflecting preferred practice within the national survey
and the recommendation of emergency obstetrics training
courses (ALSO). The pilot results therefore reflect a
slightly lower oxytocin concentration than is planned for
the multi-centre study.
Feasibility
The pilot study was conducted over an eight month period
in a unit with 3400 deliveries a year. We received approval
from the Edinburgh multi-centre research ethics commit-
tee (MREC) and approval of the UK MHRA in keeping
with the requirements of the EU directive on Clinical Tri-
als. The obstetricians, anaesthetists, midwives, theatre
staff and hospital pharmacist were very supportive. We
received a high level of support from women undergoing
caesarean section, the majority of who were happy to par-
ticipate in the trial. There were no serious unexpected
adverse events. The recruitment is summarised in the
Consort flow chart. (Figure 1)
Sample size
We estimate from the pilot study that 5–10% of study par-
ticipants will have an estimated blood loss of > 1000 ml.
The rate is around 15% for the calculated estimate (EBL-
calc) and this is more likely to be an accurate reflection of
actual blood loss. We found relative reductions of
between 20–50% in the outcome measures on comparing
infusion and placebo in the pilot study, but with wide
95% confidence intervals around these estimates. It is also
possible that a pilot study will over or under estimate dif-
ferences and we have therefore chosen conservative effect
estimates for this multi-centre study.
With 1000 patients per group for analysis, the study will
have 80% power at the 5% two-sided alpha level, to detect
differences in the proportion of patients with clinician
estimated blood loss >1000 ml of 15% vs. 10.7%, or 10%
vs. 6.4%, equivalent to odds ratios of 0.62 and 0.68
respectively.
For the co-primary outcome of calculated blood loss, and
estimated incidence in the control group of 14%, n = 1000
per group has 80% power to detect a difference 4.2%,
equivalent to odds ratio of 0.67.
Based on the hospital statistics in the Dublin Maternity
units for 2004 we estimate that there will be approxi-
mately 2500 elective caesarean sections at term each year
between the five centres. Over the course of 30 months we
would aim to recruit 2112 patients representing almost
34% of the available population (2112/6250) – this con-
servative estimate takes account of eligibility criteria and
non-English speaking women. The sample size is slightly
inflated from 2000 to allow for missing outcome data
(full blood count not taken at the correct time or blood
loss not measured).
Timetable
Total 36 months: Commencing 01.09.07 – Estimated
completion date 31.03.10
Month 0–2: Validate datasets; Raise study awareness;
Finalise recruitment procedures
Month 3–33: Recruit participants and complete docu-
mentation and follow-up
Month 34–36: Analysis; Final report; Peer-review publica-
tions; Presentations.
Governance issues
Ethical Committee Permission
Full ethical approval has previously been received for an
eight- month local pilot study designed to develop the
trial documentation and to test early feasibility issues.
05/MRE10/20 Approval date 16.03.05 MREC for Scotland
Ethical committee approval (Clinical Trials approved
Committee) from the Coombe Women's Hospital, the
National Maternity Hospital and the Rotunda Hospital,
and approval of the Irish Medicines Board have been
granted for this study.
IMB Application date 12.03.07 Approval date 27.04.07
Clinical trials approved committee Approval date
29.11.07
Data management
Data will be collected in duplicate on a case report form
(CRF) at the time of recruitment by a trained researcher.
The researcher will also be responsible for ensuring that
the details of the delivery are recorded and the blood loss
measured. The inpatient notes will be marked so that they
can easily be recovered following discharge from hospital.
After discharge the CRF will be collected by the local co-
ordinator and the completeness of the data checked
against the woman's notes. Any errors will be followed up
at this time. The data will be entered into a computer data-
base (password protected) at the Coombe Women's Hos-
pital.
Trial Management Group (TMG)
This group will be in charge of the everyday running of the
trial. The full group will meet 4-monthly and as required.
Day-to-day decision making will be by Prof Murphy, Dr
Michael Carey and the trial researcher.BMC Pregnancy and Childbirth 2009, 9:36 http://www.biomedcentral.com/1471-2393/9/36
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Oxytocin at Caesarean Section Pilot Study – CONSORT Flowchart Figure 1
Oxytocin at Caesarean Section Pilot Study – CONSORT Flowchart.
Women booked for elective 
LUSCS
(n =342) 
Not Eligible (n =55) 
¾Anticoagulated  (n =4) 
¾Preterm (n =9) 
¾Twin pregnancy (n=9) 
¾Fetal ascites (n =1) 
¾Previous classical incision (n=1) 
¾Placenta praevia/acreta (n=14) 
¾Previous PPH (n=3) 
¾Trial of labour (n=3) 
¾ECV (n=1) 
¾Polyhydramnious (n=3) 
¾GA (n=1) 
¾Incisional hernia repair (n=1) 
¾Difficult X-match (n=1) 
¾Portal vein varices (n=1) 
¾Uterine fibroid (n=1) 
¾IUD (n=1) 
¾Tubal ligation (n=1) 
Eligible women (n = 287) 
Not consented (n =172) 
¾ Not approached (n=115)  
¾ Delivered prior to booked date 
(n=31) 
¾ Declined (n =26)  
Randomised (n = 115) 
Syntocinon Infusion 
(n=56) 
Placebo
(n=54) 
Protocol violation (n=5) 
¾ GA (n=2) 
¾ Previous PPH (n=1) 
¾ Midwife error (n=1) 
¾ Myomectomy (n=1) BMC Pregnancy and Childbirth 2009, 9:36 http://www.biomedcentral.com/1471-2393/9/36
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Trial Steering Committee
A trial steering committee will be set up which will have
overall supervision of the trial. It will meet prior to com-
mencement of the trial and then at least 6 monthly until
completion. A meeting of the TSC will be held within a
month of every DMEC meeting to consider their recom-
mendations. An independent Chair will be sought for the
TSC.
Data monitoring and Ethics Committee (DMEC)
An independent safety and data monitoring committee
will also be formed. They will meet yearly to examine
recruitment figures, baseline data, retention and adverse
events. The DMEC will not undertake any formal interim
analyses for either safety or effectiveness and therefore
there are no formal stopping rules. There is no evidence of
adverse reactions associated with oxytocin infusion.
Although adverse reactions have been shown to be associ-
ated with the 5 IU oxytocin bolus, all trial participants will
receive a bolus, and thus we do not anticipate any differ-
ences in rates of adverse events between the groups. How-
ever all adverse events will be reported to the DMEC who
will report these data to the Trial Steering Committee.
Additionally, in the event of a postpartum haemorrhage,
clinicians are permitted to discontinue the trial infusion
and commence a known 40 IU oxytocin infusion.
Safety considerations
Serious or unexpected serious adverse reactions (SUSARs)
will be recorded and reported using the IMB approved
SUSAR form. SUSARs include maternal death, surgery
(other than caesarean section) in the 2 weeks following
randomisation, transfusion of over 4 units of blood,
admission to intensive care unit or suspected drug reac-
tions. In the event of a SUSAR the form will be completed
by the local trial co-ordinator and faxed to the trial co-
ordinating centre at the Coombe Women's Hospital
within 72 hours. From there the copies of the form will be
sent to the trial statistician for unblinding and the chair of
the Data Monitoring and Ethics Committee (DMEC). The
IMB, the trial sponsor and the Chair of the MREC will also
be informed by the DMEC Chair if considered appropri-
ate.
Discussion
Potential and Implementation of the findings
It is both important and timely that we evaluate the opti-
mal approach to the management of the third stage at
elective caesarean section. The caesarean section rate has
risen dramatically over the last two decades and continues
to rise. Safe operative delivery is now a priority and a real-
ity for many pregnant women. Obstetricians, obstetric
anaesthetists, midwives and pregnant women need high
quality evidence on which to base management
approaches. The use of oxytocin in this context is a poorly
evaluated component of obstetric care. The overall aim is
to reduce maternal haemorrhagic morbidity and its
attendant risks at elective caesarean section. In addition
we will develop a protocol establishing the economic
implications and patient perspective of the two
approaches.
Dissemination
We aim to raise awareness of this clinical question and our
proposed research approach at both local and national
meetings. A final report will be prepared for the funding
body and papers will be prepared for peer-review publica-
tion and national/international dissemination.
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